The MuLBSTA score—which incorporates multilobe infiltrate, absolute lymphocyte count ≤0.8 x 109/L, bacterial coinfection, smoking history, history of hypertension and age ≥60 years—was recently developed in China to predict 90-day mortality in patients with viral pneumonia. With the score taking into account some of the factors that make COVID-19 unique, US researchers explored the applicability of MuLBSTA scores in predicting disease severity and mortality risk in patients with COVID-19. When applied to each patient at time of hospitalization, MuLBSTA had mean scores of 8.67 for patients who survived and 13.6 for those who died. A significant positive correlation of MuLBSTA score with mortality (odds ratio p[OR], 1.37) was observed. A positive correlation was also seen with need for ventilator support (OR, 1.30) and length of stay. The area under the receiver operatic characteristic curve of MuLBSTA for predicting in-hospital mortality at time of admission was 0.813. The study authors suggest MuLBSTA score could help direct treatment type in this patient population.
October 30, 2020
October 9, 2019
October 11, 2019
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.